Drug Profile

Mucin 1 targeting antibody - Protheragen

Alternative Names: Anti-MUC1-Ab

Latest Information Update: 16 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Protheragen
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Acute myeloid leukaemia

16 Aug 2022 Protheragen has patent protection for anti-MUC-1 antibody prior to August 2022 (Protheragen website, August 2022)
16 Aug 2022 Preclinical development in Solid tumours in USA (Parenteral) prior to August 2022 (Protheragen website, August 2022)
19 Jun 2020 Mucin 1 targeting antibody is available for licensing as of 19 Jun 2020. https://www.protheragen.com/pipeline.html

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com